The US Patent and Trademark Office told a group of specialized patent judges on Tuesday afternoon they could be expected to ...

On January 27, in Apple Inc. v. Gesture Technology Partners, LLC, the Federal Circuit held that the Patent Trial and Appeal ...

On Jan. 29, 2025, the U.S. Patent and Trademark Office (USPTO) released statistics regarding the number and type of contested proceedings brought ...

The first day of IPWatchdog’s PTAB Masters 2025 wrapped up with a session in which three IP luminaries weighed in on the ...

Kristina Caggiano Kelly, David H. Holman and Lestin L. Kenton Jr. of Sterne, Kessler, Goldstein & Fox PLLC discuss a Federal ...

In a significant ruling Monday, a Federal Circuit panel upheld two Patent Trial and Appeal Board (PTAB) decisions that invalidated claims in two patents held by USAA, one of which underpinned a ...

The Patent Trial and Appeal Board has jurisdiction to review patents’ validity even after their expiration, the Federal Circuit ruled in an opinion wiping out the last surviving claim from a camera ...

Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today ...

Atossa Therapeutics (ATOS) issued the following statement in response to the Patent Trial and Appeal Board’s, PTAB, final written decision in ...